Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of painful diabetic peripheral neuropathy.
Product Name : JAN101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2023
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of painful diabetic peripheral neuropathy.
Product Name : JAN101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recent studies have in fact suggested that PAD is a microvascular disease, so the observation that JAN101 (Sodium nitrite) improves microvascular and nerve function is crucial in treating this disease.
Product Name : JAN101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : SPYR Technologies
Deal Size : $13.5 million
Deal Type : Divestment
JanOne Sells GeoTraq to SPYR Technologies in a $13.5 Million Transaction
Details : Sale of GeoTraq, a wholly-owned subsidiary of JanOne to SPYR Technologies will help main business continue to fund the necessary clinical trials for JAN101 (TV1001SR), a slow-release formulation of sodium nitrite used for treatment for peripheral artery ...
Product Name : JAN101
Product Type : Other Small Molecule
Upfront Cash : $13.5 million
May 31, 2022
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : SPYR Technologies
Deal Size : $13.5 million
Deal Type : Divestment
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JAN101 is a patented sustained release form of sodium nitrite aimed at improving vascular function, reducing neuropathic pain and other conditions resulting from poor blood flow for treatment of Peripheral Artery Disease (PAD).
Product Name : JAN101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in the near future. JAN101 is highly selective, acting only in damaged tissue.
Product Name : JAN101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2021
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
JanOne as Trial Manager for Phase 2b Study of JAN101 Peripheral Artery Disease
Details : The primary endpoint will be the ability of patients to walk without pain or muscle fatigue as a result of vascular function restored by JAN101.
Product Name : JAN101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2021
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JAN101 is intended to address the 8.5 million Americans who may have PAD. One of the more encouraging outcomes from patients who participated in early Phase 1 and Phase 2a trials of JAN101 was a reported reduction in associated PAD pain.
Product Name : JAN101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2021
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Alliance Global Partners
Deal Size : $6.0 million
Deal Type : Public Offering
JanOne Announces Closing of $6.0 Million Common Stock Offering
Details : The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including planning of clinical trials for JAN101, the company’s lead drug candidate.
Product Name : JAN101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 02, 2021
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Alliance Global Partners
Deal Size : $6.0 million
Deal Type : Public Offering
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JanOne together with its manufacturing partner, has successfully completed the formulation of JAN101, its potential treatment for Peripheral Artery Disease (PAD) expected to soon be in Phase 2b trials.
Product Name : JAN101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2020
Lead Product(s) : Sodium Nitrite
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable